Driven by a meaningful improvement in net profit margin and a notable drop in future P/E, analysts have modestly raised Everest Medicines’ fair value, with the consensus price target increasing from HK$62.67 to HK$64.56.
What's in the News
- Everest Medicines expects full-year 2025 revenue of RMB 1.6–1.8 billion, with RMB 1.2–1.4 billion from NEFECON sales.
- Board meeting scheduled to discuss interim results for the first half of 2025.
- Completed a follow-on equity offering, raising HKD 1.572502 billion through the issuance of 22,561,000 shares at HKD 69.7 per share via direct listing.
- Ordinary shares are subject to a 91-day lock-up period ending 31-OCT-2025, restricting certain transactions.
- Filed the follow-on equity offering prior to completion, indicating successful capital raising initiatives.
Valuation Changes
Summary of Valuation Changes for Everest Medicines
- The Consensus Analyst Price Target has risen slightly from HK$62.67 to HK$64.56.
- The Net Profit Margin for Everest Medicines has significantly risen from 21.17% to 24.42%.
- The Future P/E for Everest Medicines has significantly fallen from 33.36x to 29.16x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.